Objectives α-synuclein aggregation is an indicator of neurodegenerative diseases such as Parkinson’s disease (PD) and recent advances have suggested that this protein could serve as a potential biomarker. It has been indicated that soluble and oligomeric α-synuclein in biological fluids could have diagnostic applications for PD. Clinical laboratories currently rely on antibody-based assays to detect α-synuclein. These assays have limited specificity, low sensitivity and poor inter-lab reproducibility, which prevents the validation of α-synuclein as a biomarkers. This study aims to fill the unmet need for the standardisation of clinical measurements for α-synuclein. Methods We report the first candidate reference method for α-synuclein, using an SI traceable primary calibrator for α-synuclein and isotope dilution mass spectrometry. The primary calibrator was traceably quantified utilising a combination of amino acid analysis and nuclear magnetic resonance. A targeted sample clean-up procedure involving a non-denaturing Lys-C digestion and solid-phase extraction allowed for the sensitive detection of multiple proteotypic α-synuclein peptides in cerebrospinal fluid (CSF) samples. Results The candidate reference method procedure showed linearity across three orders of magnitude, covering the physiological levels of α-synuclein in CSF (LOQ = 0.1 ng/g). The method was used to quantify a cohort of CSF samples and the measurements were correlated with immunoassay-based quantifications. Conclusions The SI traceable quantification of α-synuclein in complex biological matrices means that the role of this protein can be further elucidated in synucleinopathies. This candidate reference method would lead to the harmonisation of α-synuclein measurements, which may allow for development of high throughput clinical tests.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: